Lynch syndrome is best known as an inherited cause of colon and womb cancer, and breast cancer has long sat at the edge of that list. The link appears real but modest, and it seems to depend on which of the Lynch genes a person carries.1Columbia University Irving Medical Center. Two New Breast Cancer Genes Emerge from Study of Lynch Syndrome For most people with Lynch syndrome, breast cancer risk shapes screening decisions far less than their colon and womb cancer risk does.
Why Breast Cancer Was Never Clearly On The Lynch List
Lynch syndrome is caused by an inherited change in one of four genes, MLH1, MSH2, MSH6 or PMS2, and your genetic report will name which one.2PubMed Central. Lynch syndrome, molecular mechanisms and variant classification These mismatch repair genes fix the copying errors cells make each time they divide.3Hereditary Genetics. Lynch Syndrome Genes and Functions of DNA Mismatch Repair Proteins When one of them fails, errors pile up in cells and cancers can develop.4PubMed Central. Lynch syndrome, molecular mechanisms and variant classification The classic Lynch cancers are colon and womb cancer, with ovarian, urinary tract and stomach cancers also raised.5PubMed. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
The evidence on breast cancer has been split. Of 21 studies looking at breast cancer risk in Lynch syndrome, 13 found no rise and 8 found a higher risk.6PubMed Central. Risk of breast cancer in Lynch syndrome: a systematic review The studies that did find a rise ranged from about double to many times the usual risk.7PubMed Central. Risk of breast cancer in Lynch syndrome: a systematic review So the answer depended heavily on which families and genes were studied.
Part of the confusion is that breast cancer is common, about 1 in 8 women in many countries, so it turns up in most large families. A few breast cancers in a Lynch family may be coincidence rather than Lynch, which makes the true link hard to see without large studies.
A small rise in risk is also hard to detect. A study needs many carriers to tell a true increase from chance, and many early Lynch studies were small. Some counted breast cancers in families already chosen because they had many cancers, which can overstate risk compared with carriers found through ordinary testing. Others lumped all four genes together, which can hide a rise in one gene by averaging it with genes that show none.
If you only heard that you “have Lynch syndrome,” go back to the report or your clinic to find the exact gene, because the rest of this article depends on it. Older family-based studies often didn’t separate the genes, which is one reason older advice can sound vaguer than current thinking.
Your Risk Depends On Which Lynch Gene You Carry
Women with MSH6 or PMS2 changes appear to have about twice the usual breast cancer risk.8PubMed Central. MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer An estimated 31% to 38% may develop breast cancer in their lifetime, against about 15% of women generally.9Columbia University Irving Medical Center. Two New Breast Cancer Genes Emerge from Study of Lynch Syndrome In a population-based Australian breast cancer study, all the Lynch changes found in women with breast cancer were in MSH6 or PMS2.10PubMed. Mismatch repair gene pathogenic germline variants in a population-based cohort of breast cancer PMS2 carriers otherwise show the lowest overall cancer risk of the four genes.11PubMed. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
The 31% to 38% estimate is a population average from studies, not a prediction for one woman. A woman with an MSH6 or PMS2 change is still more likely not to develop breast cancer than to develop it.
The picture for MLH1 and MSH2 is less clear. One large analysis found no clear rise in breast cancer for MLH1 or MSH2 carriers.12PubMed Central. MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer A UK family study, though, found about 18.6% of MLH1 carriers had breast cancer by 70, versus about 7.5% to 8% of UK women.13PubMed. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study The same study put MSH2 carriers at about 11.2% by 70.14PubMed. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study For these two genes, any added breast risk is uncertain and possibly small.
The lifetime figures don’t line up neatly. Some stop at age 70 and others run to a full lifetime, and a longer window naturally gives a higher percentage. The studies also drew on different groups, such as families seen in specialist clinics versus carriers found more broadly. So the 18.6% by age 70 for MLH1 and the 31% to 38% for MSH6 or PMS2 shouldn’t be compared as if they were measured the same way.
Your gene result is only one input. Relatives with breast cancer, especially at young ages, can push your personal risk above the average for your gene, while a family with no breast cancer may put you nearer or below it.
Breast cancer also ranks lower than your other Lynch risks. For MLH1 and MSH2 carriers, colon and womb cancer risks are far larger than any breast risk. For MSH6 carriers, womb cancer is the main concern, with breast risk secondary. For PMS2 carriers, a doubled breast risk sits within a generally lower-risk picture.
Do You Need Extra Breast Screening
Current guidelines generally advise Lynch carriers to follow the same breast screening as the general population. A roughly doubled risk still sits below the level that usually triggers extra scans. Extra screening such as MRI is reserved for people whose overall risk crosses a set threshold, and MRI can flag harmless findings that lead to more tests and biopsies, so it is used where the benefit is likely to outweigh that cost.
Some women do cross that threshold. In one group of women with Lynch syndrome, 7.5% without cancer had an estimated lifetime breast risk above 20%.15PubMed Central. Investigating the Link between Lynch Syndrome and Breast Cancer Those women would qualify for yearly breast MRI, which otherwise would not be offered.16PubMed Central. Investigating the Link between Lynch Syndrome and Breast Cancer
About a quarter of Lynch patients in that same group also qualified for separate breast cancer gene testing.17PubMed Central. Investigating the Link between Lynch Syndrome and Breast Cancer So ask for a formal breast risk estimate using your family history, and tell your doctor which Lynch gene you carry, since MSH6 and PMS2 matter most here.
A genetic counselor or breast clinic will ask which relatives had breast or ovarian cancer and how old they were at diagnosis, so gather this before your visit. They combine that history with your gene result in a risk calculator that gives an estimated lifetime percentage. Above about 20%, yearly MRI alongside mammograms is usually offered. The estimate can change, so it is worth repeating when a new cancer is diagnosed in the family.
Between scans, knowing how your breasts normally look and feel makes a change easier to notice. Report a new lump, skin dimpling, nipple change or discharge promptly. Don’t wait for the next scheduled mammogram, because screening is no substitute for checking a symptom.
When Lynch Syndrome Actually Causes A Breast Cancer
Some breast tumors in carriers do carry the Lynch fingerprint. In breast cancers from Lynch carriers, about 42% had lost the repair proteins.18Clinical Cancer Research. Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome On a pathology report these tumors are called mismatch repair deficient or MSI-high, meaning the faulty repair drove the cancer.19PubMed Central. Breast cancer in Lynch Syndrome patients: genomic and pathologic evidence in support of a potential causal relationship All of these tumors were hormone receptor positive.20PubMed Central. Breast cancer in Lynch Syndrome patients: genomic and pathologic evidence in support of a potential causal relationship The other tumors looked like ordinary breast cancers that may have arisen by chance.21Clinical Cancer Research. Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome
Most breast cancers in carriers look typical. About 91% were estrogen receptor positive and 85% HER2 negative, the same as in non-carriers.22PubMed Central. Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases Treatment usually follows the same standard plans.
Pathologists stain the tumor for the four repair proteins, and a missing protein suggests the repair system has failed in that tumor. Some labs instead test for MSI directly, looking for the pattern of copying errors that failed repair leaves behind. If the missing protein matches the gene you inherited, that supports the cancer being linked to your Lynch change.
If your tumor didn’t show the Lynch fingerprint, your Lynch result is not wrong. You still carry the gene change and your other Lynch risks stand. It suggests this particular breast cancer may have arisen by chance, and it is treated according to its own features, like any other breast cancer.
Tumor testing for repair loss isn’t always done automatically for breast cancer, so asking whether it was done is reasonable. A positive result ties the cancer to your Lynch gene, which helps your team interpret your history, and it can open the door to immunotherapy if the cancer later spreads.
How Lynch Syndrome Can Change Breast Cancer Treatment
Tumors with faulty repair carry many mutations, which makes them easier for the immune system to recognize. Their cells display many abnormal proteins the immune system can read as foreign. Tumors often switch on checkpoints that hide them from immune cells, and checkpoint inhibitors release that brake. Drugs of this kind, such as pembrolizumab, are approved for MSI-high cancers in many countries. They are tied to the tumor’s repair status, not to where in the body the cancer began.
Breast cancer has seen some striking responses. In one reported case, a Lynch carrier’s triple-negative breast cancer disappeared on scans after pembrolizumab alone.23PubMed Central. Pembrolizumab Monotherapy for Early-Stage Triple-Negative Breast Cancer in a Patient With Lynch Syndrome In another, an advanced hormone-positive MSI-high breast cancer shrank and the woman returned to work.24PubMed Central. Pembrolizumab response in stage IV luminal-type breast cancer with high microsatellite instability: a case report
These are single cases that show what is possible, not how often it happens. These drugs can also have significant side effects, so the decision weighs expected benefit against those risks.
Questions worth taking to your cancer team: Has my tumor been tested for MSI or mismatch repair loss, since immunotherapy decisions depend on it? Could immunotherapy be an option now, or only if the cancer returns or spreads? Does my Lynch gene change decisions about surgery or screening of my other breast?
Testing For Lynch And Other Breast Cancer Genes Together
Modern genetic tests check many genes at once, including the four Lynch genes. A panel can show a Lynch change, a BRCA change, both, or neither. In one large study, about 3.6% of breast cancer patients had a harmful Lynch gene change, against 0.4% of healthy people.25PubMed Central. Lynch Syndrome Germline Mutations in Breast Cancer: Next Generation Sequencing Case-Control Study of 1,263 Participants In a population-based study, only about 0.4% of women with breast cancer carried one.26PubMed. Mismatch repair gene pathogenic germline variants in a population-based cohort of breast cancer
If your Lynch result came from a narrow test, a broader panel may still be worth discussing when breast cancer runs in your family. BRCA and some other breast genes carry much higher breast risk than Lynch genes, so missing one would change your screening plan.
Some people carry two cancer genes. People can inherit both a BRCA change and a Lynch change.27PubMed. Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications Across reported cases, carrying two such genes was linked to earlier cancers and more of them.28PubMed Central. Multilocus Inherited Neoplasia Alleles Syndrome in a Patient With BRCA2‐Associated Breast Cancer and MLH1‐Related Lynch Syndrome Yet in one series of Ashkenazi Jewish families, double carriers of BRCA and MSH2 or MSH6 did not get cancer earlier.29PubMed. Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications So if you have Lynch syndrome and a strong breast cancer family history, ask whether BRCA testing has been done.
Because Lynch and BRCA changes are inherited, telling relatives about your result lets them consider their own testing and begin screening early.